Highlights of This Issue 4303

SPECIAL FEATURES

Editorial

4305 Food and Oral Antineoplastics: More Than Meets the Eye
Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko
See article p. 4446

CCR Translations

4308 Personalized Tamoxifen: A Step Closer but Miles To Go
Aditya Bardia and Vered Stearns
See article p. 4468

4311 Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia
Dennis J. Goussetis and Leonidas C. Platanias
See article p. 4382

CCR New Strategies

4313 New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts
Donghui Li and James L. Abbruzzese

Molecular Pathways

4319 Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka, Takahito Hara, and Masami Kusaka

4325 PI(3)K Apart PTEN's Role in Cancer
Siyuan Zhang and Dihua Yu

Report from the FDA

4331 U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougall, Anne Pilano, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

HUMAN CANCER BIOLOGY

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara de Bruwuer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeeck, Tom Van Maerken, Anne De Paep, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Egger, Jan Cools, Rogier Versteeg, and Frank Speleman

Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
Shih-Sheng Jiang, Wen-Tsen Fang, Ya-Hsue Hou, Shiu-Feng Huang, B. Linju Yen, Junn-Liang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang
### CANCER THERAPY: PRECLINICAL

| Page |
|-------|-----------------|-----------------|
| 4382  | *Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation*<sup>1</sup> | 4434 | *Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer*<sup>2</sup> |
|       | Javier Redondo-Muñoz, Elizabet Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo | See commentary p. 4311 | See commentary p. 4311 |

*<sup>1</sup>See commentary p. 4311<br><sup>2</sup>See commentary p. 4311

### CANCER THERAPY: CLINICAL

| Page |
|-------|-----------------|
| 4446  | *Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products*<sup>3</sup> | 4542 | *Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients*<sup>4</sup> |

*<sup>3</sup>See commentary p. 4315<br><sup>4</sup>See commentary p. 4311

### IMAGING, DIAGNOSIS, PROGNOSIS

| Page |
|-------|-----------------|-----------------|
| 4401  | *Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer*<sup>5</sup> | 4452 | *Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients*<sup>6</sup> |

*<sup>5</sup>See commentary p. 4315<br><sup>6</sup>See commentary p. 4311
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch

See commentary p. 4308

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli
Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch

See commentary p. 4308

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants